参附强心丸对慢性心力衰竭神经内分泌及相关因子的调节作用

邓颖; 江玉; 秦佰焰

doi:10.13422/j.cnki.syfjx.2014150204

您当前的位置：

首页 >

文章列表页 >

参附强心丸对慢性心力衰竭神经内分泌及相关因子的调节作用

临床 | 更新时间：2024-01-04

- 参附强心丸对慢性心力衰竭神经内分泌及相关因子的调节作用
- Regulating Effect of Shenfu Qiangxin Pills on Neural Endocrine and Related Factors of Chronic Heart Failure
- 中国实验方剂学杂志 2014年20卷第15期页码：204-207
- 作者机构：
- 作者简介：
- 基金信息：
  
  四川省教育厅项目（川教函[2011]538号11ZB130）
- DOI：10.13422/j.cnki.syfjx.2014150204
  中图分类号： R285.6
- 纸质出版日期：2014
- 稿件说明：
移动端阅览
邓颖, 江玉, 秦佰焰. 参附强心丸对慢性心力衰竭神经内分泌及相关因子的调节作用[J]. 中国实验方剂学杂志, 2014,20(15):204-207.

DENG Ying, JIANG Yu, QIN Bai-yan. Regulating Effect of Shenfu Qiangxin Pills on Neural Endocrine and Related Factors of Chronic Heart Failure[J]. Chinese journal of experimental traditional medical formulae, 2014, 20(15): 204-207.
邓颖, 江玉, 秦佰焰. 参附强心丸对慢性心力衰竭神经内分泌及相关因子的调节作用[J]. 中国实验方剂学杂志, 2014,20(15):204-207. DOI： 10.13422/j.cnki.syfjx.2014150204.

DENG Ying, JIANG Yu, QIN Bai-yan. Regulating Effect of Shenfu Qiangxin Pills on Neural Endocrine and Related Factors of Chronic Heart Failure[J]. Chinese journal of experimental traditional medical formulae, 2014, 20(15): 204-207. DOI： 10.13422/j.cnki.syfjx.2014150204.

摘要

目的：探讨参附强心丸对慢性心力衰竭（CHF）患者肾素-血管紧张素-醛固酮系统（RAAS）及心房利钠多肽（ANP）和脑利钠多肽（BNP）的影响。方法：90例CHF患者随机按诊病前后分为西药组和观察组各45例。西药组服用依那普利片，5 mg/次，2次/d；倍他乐克片，0.1 g/次，2次/d；地高辛片，0.25 mg/次，1次/d，必要时服用。观察组在西药组治疗的基础上加用参附强心丸，6 g/次，3次/d。两组疗程均为12周。采用超声心动图测定左室舒张末期内径（LVED）、收缩末期内径（LVSD）、心室射血分数（LVEF）和心输出量（CO），记录Lee氏心衰计分和6 min步行实验（6 MWT）评分，检测抗利尿激素（ADH）、N末端前脑利钠肽（NT-proBNP）、血管紧张素Ⅱ （AngⅡ）和醛固酮水平，治疗前后各评定1次。结果：观察组Lee氏心衰疗效总有效率为86.67%，西药组为68.89%，观察组优于西药组（P<0.05）；治疗后观察组LVED和LVSD小于西药组（P<0.01）；治疗后两组LVEF和CO都有增加（P<0.01），观察组LVEF和CO增加更为显著（P<0.01）；两组治疗后Lee氏心衰积分比治疗前下降，观察组低于西药组（P<0.01）；两组治疗后6 MWT均比治疗前有所改善，观察组改善更为显著（P<0.01）；治疗后观察组血AngⅡ、醛固酮水平、NT-proBNP和ADH水平均低于西药组（P<0.01）。结论：在西医常规治疗的基础上参附强心丸能进一步改善CHF患者心功能，并能抑制RAAS系统，调节ANP和BNP，逆转心室重塑，这可能是其重要的作用机制。

Abstract

Objective: To observe influence of Shenfu Qiangxin pills to patients' renin-angiotensin-aldosterone system(RAAS)

atrial natriuretic polypeptide(ANP) and brain natriuretic peptide(BNP) in treating chronic heart failure(CHF). Method: Ninety cases with CHF were randomly divided into control group (45 cases) and observation group (45 cases) by diagnosis time.Patients in control group received enalapril tablets with 5 mg/time and 2 times/day;Metoprolol tablets with 0.1 g/time and 2 times/day. Digoxin tablets with 0.25 mg/time and 1 time/day

everyone took necessarily.Based on the treatment of control group

patients in observation group received Shenfu Qiangxin pills with 6 g/time and 3 times/day.Course of treatment in two groups were both 12 weeks.Left ventricular end diastolic(LVED)

left ventricular end systolic diameter(LVSD)

left ventricular ejection fraction(LVEF) and cardiac output(CO)were detected by echocardiogram

Lee's heart failure scores and six-minute walk test(6 MWT) were recorded

levels of antidiuretic hormone(ADH)

N-terminal pro-brain natriuretic peptide(NT-proBNP)

angiotensin-Ⅱ(AngⅡ) and aldosterone were detected

all of those were evaluated for one time before and after treatment. Result: Total effective rate of curative effect of Lee's heart failure scores in the observation group was 86.67% superior to 68.89% of which in the control group(P<0.05). After treatment

LVED and LVSD in the observation group were small than those in the control group(P<0.01)

LVEF and CO in both groups increased(P<0.01)

and which increased more dramaticlly in the observation group than in the control group(P<0.01).Compared with the time before treatment

integral of Lee's heart failure scores decreased

and which in the observation group were lower than those in the control group(P<0.01). 6 MWT in both groups also ameliorated

and which was more significant in the observation group than in the control group(P<0.01);Levels of haematic AngⅡ

aldosterone

NT-proBNP and ADH in the observation group were lower than those in the control group(P<0.01). Conclusion: Based on the treatment of conventional western medicine

Shenfu Qiangxin pills could ameliorate further cardiac function of patients' with CHF

inhibit RAAS

adjust ANP and BNP and reverse ventricle remodeling

those may be key mechanism of action of this preparation.

关键词

Keywords

references

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

参附强心丸对慢性心力衰竭心功能及对脑钠素及炎性因子水平的影响

基于中西医病证结合特点的慢性心力衰竭动物模型分析

升陷汤对慢性心力衰竭大鼠心肌微血管损伤的保护作用

慢性心力衰竭气虚血瘀证预测模型的构建与验证

益气温阳活血利水组分配伍对CHF大鼠心功能及心肌能量代谢的影响